Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that a specific amino-pyridine compound showed potent androgen receptor antagonist activity, stimulating hair growth in mice and reducing sebum production in a hamster model.

This study found that two synthesized androst-4-ene-3-one derivatives, 6f and 6g, exhibited stronger anti-proliferative effects than common drugs on prostate cancer cell lines, with low toxicity to rat cells.

This study found that arylhydantoin and arylthiohydantoin derivatives with hydroxybutyl or methyl side-chains showed superior androgen receptor binding affinity and may serve as promising radioiodinated AR ligands.

This study found that stress-associated hair loss may be linked to increased androgen receptor expression and activity in non-balding hair follicles due to dexamethasone treatment.

This study discusses the complex roles and effects of brain-synthesized sex neurosteroids, highlighting sex differences in their concentrations and their varied impacts on synaptic plasticity, cognitive behavior, and aging-related cognitive decline.

This review provides an overview of clinically approved small molecule drugs targeting androgen receptors and discusses therapeutic applications, without presenting new experimental results.

In this study, all stereoisomers of cyoctol were synthesized and tested, revealing that contrary to initial patent claims, cyoctol does not function as an anti-androgen.

This study aimed to develop a new transdermal patch for treating androgenetic alopecia using finasteride, combined with chemical permeation enhancers to improve drug delivery through the skin, but results of pharmacokinetics and pharmacodynamics evaluations are not reported.

This study identified the N-(iodopropenyl) derivative 13 as a promising candidate for development as a radioiodinated androgen receptor ligand due to its binding affinity.

This research found that androgen bioactivity plays a role in normal female sexual differentiation, suggesting females develop within a significant androgenic environment, with implications for understanding conditions like congenital adrenal hyperplasia.

This study found that the compound androstane-17-carboxamide 6 may serve as a lead for new drugs to treat BPH and prostate cancer by reducing the weight of androgen-dependent glands.

This study found that castration-resistant prostate cancers resistant to CYP17A1 inhibitors may still depend on steroids and could respond to therapies targeting de novo intratumoral steroid synthesis.

This study found that novel androgen antagonists incorporating a carborane moiety showed anti-androgenic activity comparable to flutamide in a laboratory setting.

This study found that despite the presence of steroidogenesis inhibitors, CRPC tumor cells adapt to continue synthesizing androgens, suggesting a need for more effective androgen axis targeting.

This study found that glioblastoma cells express key enzymes involved in androgen synthesis, suggesting these enzymes might be potential targets for new therapeutic strategies.

In this study, using a 3D culture model, researchers observed that developmental stage and androgen levels influenced murine follicle growth, which may inform treatment for women with low ovarian reserve but cautions against excessive androgen exposure.

This chapter discusses androgen receptors and protein synthesis in the prostate, reporting that DHT-dependent receptor protein translocation increases protein-synthesizing activity after androgen injection in rat models.

This study suggests that PF-0998425 is an effective androgen receptor antagonist for sebum control and androgenetic alopecia with rapid metabolism reducing the risk of systemic side effects.

This study identified 30 new compounds with significant androgen receptor binding affinity through a combination of virtual screening and in vitro testing.

This review discusses the current understanding of androgen biosynthesis, mechanisms of action, and their roles in human biology, as well as related congenital and acquired disorders, but it reports no new research findings.

This study synthesized nonsteroidal ligands as second-generation androgen receptor agonists and identified three compounds with significant anabolic activity and moderate to minimal androgenic activity in vivo.

This review discusses the potential antiandrogenic effects of environmental chemicals on reproductive development, highlighting concerns about their impacts on humans but reports no new clinical findings.

This study found that a novel thiohydantoin derivative, 3a, effectively inhibited androgen receptor activity in LNCaP cells and showed promising in vivo results by reducing testosterone-induced prostate changes, outperforming finasteride in mitigating prostate index and histopathological alterations.

This study suggests that the testosterone analogs 7α-Methyltestosterone and 7α-Ethyltestosterone may offer promising androgenic, progestogenic, and anabolic properties for development as male contraceptives.

This study suggests that stress-associated hair loss may occur due to increased androgen receptor expression and activity induced by dexamethasone in human and mouse dermal papilla cells.

This study found that some synthesized 17-oximino-5-androsten-3β-yl esters demonstrated stronger cytotoxicity and antiandrogenic activity against prostate cancer cells than finasteride.

This study identified compounds 11d and 11k as potential dual 5α-reductase inhibitors and AR antagonists with significant anti-proliferative effects on prostate cancer cell lines, suggesting they may offer therapeutic value.

This review synthesizes existing research on autologous platelet-rich plasma for treating androgenetic alopecia, suggesting its promise with standardized protocols and personalized approaches, but reports no new clinical results.

This study found that using anhydrous cerium(III) chloride with alkyl Grignard reagents significantly improved the addition to sterically hindered 17-ketosteroids, resulting in high yields and stereoselectivity.

This review discusses low-dose oral minoxidil for adult androgenetic alopecia and female pattern hair loss and reports no clinical results; it provides a transparency archive with review materials.